Effects of clotrimazole on the growth, morphological characteristics, and cisplatin sensitivity of human glioblastoma cells in vitro

Journal of Neurosurgery

Volumn 90, Issue 5, 1999, Pages 918-927

  Khalid, M Humayun ^a   Shibata, Shobu ^a   Hiura, Tsuyoshi ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin cytotoxicity; Clotrimazole; Differentiation; Glial fibrillary acidic protein; Glioblastoma multiforme; Wild type p53

Indexed keywords

CISPLATIN; CLOTRIMAZOLE; GLIAL FIBRILLARY ACIDIC PROTEIN; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; COLORIMETRY; CONTROLLED STUDY; DRUG CYTOTOXICITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; PRIORITY JOURNAL;

EID: 0032960276     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1999.90.5.0918     Document Type: Article

References (50)

1. 2+ stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. Proc Natl Acad Sci USA 95:8280-8285,1998
2. + channels by cytochrome p-450 inhibitors. J Biol Chem 267:11789-11793, 1992
3. Anker L, Ohgaki H, Ludeke BI, et al: p53 protein accumulation and gene mutations in human glioma cell line. Int J Cancer 55: 982-987, 1993
4. Benzaquen LR, Brugnara C, Byers HR, et al: Clotrimazole inhibits cell proliferation in vitro and in vivo. Nature Med 1: 534-541, 1995
5. Bianchi Scarrà GL, Romani M, Coviello DA, et al: Terminal erythroid differentiation in the K-562 cell line by 1-β-D-arabinofuranosylcytosine: accompaniment by c-myc messenger RNA decrease. Cancer Res 46:6327-6332, 1986
6. Blagosklonny MV, El-Deiry WS: Acute overexpression of WT p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer 75:933-940, 1998
7. Brenner M: Structure and transcriptional regulation of the GFAP gene. Brain Pathol 4:245-257, 1994
8. Broaddus WC, Chen ZJ, Prabhu SS, et al: Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells. Neurosurgery 41:908-915, 1997
9. Brodie C, Goldreich N: Interleukin-4 modulates the proliferation and differentiation of glial cells. J Neuroimmunol 35: 91-97, 1994
10. Burns KD, Capdevila J, Wei S, et al: Role of cytochrome p-450 epoxygenase metabolites in EGF signaling in renal proximal tubule. Am J Physiol 269:C831-C840, 1995
11. Caliaro MJ, Vitaux P, Lafon C, et al: Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. Br J Cancer 75:333-340, 1997
12. Chader GJ: Multipotential differentiation of human Y-97 retinoblastoma cells in attachment culture. Cell Differ 20: 209-216, 1987
13. Chung R, Whaley J, Kley N, et al: TP53 gene mutations and 17p deletions in human astrocytomas. Genes Chrom Cancer 3:323-331, 1991
14. Clarke AR, Purdie CA, Harrison DJ, et al: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852, 1993
15. Dorigo O, Turla ST, Lebedeva S, et al: Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J Neurosurg 88:535-540, 1998
16. Ebert PS, Salcman M: Differentiation therapy is potentiated by chemotherapy and hyperthermia in human and canine brain tumor cells in vitro. Neurosurgery 34:657-664, 1994
17. Engelhard HH, Duncan HA, Dal Canto M: Molecular characterization of glioblastoma cell differentiation. Neurosurgery 41:886-897, 1997
18. Engelhard HH III, Butler AB IV, Bauer KD: Quantification of the c-myc oncoprotein in human glioblastoma cells and tumor tissue. J Neurosurg 71:224-232, 1989
19. Fajac A, Da Silva J, Ahomadegbe JC, et al: Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 68:67-74, 1996
20. Fischer I, Nolan CE, Shea TB: Effects of retinoic acid on expression of the transformed phenotype in C6 glioma cells. Life Sci 41:463-470, 1987
21. Fukuyama K, Matsuzawa K, Hubbard SL, et al: Analysis of glial fibrillary acidic protein gene methylation in human malignant gliomas. Anticancer Res 16:1251-1257, 1996
22. Gowda SD, Koler RD, Bagby GC Jr: Regulation of C-myc expression during growth and differentiation of normal and leukemic human myeloid progenitor cells. J Clin Invest 77: 271-278, 1986
23. Hirvonen HE, Salonen R, Sandberg MM, et al: Differential expression of myc, max and RB1 genes in human gliomas and glioma cell lines. Br J Cancer 69:16-25, 1994
24. Ito M, Nagashima T, Hoshino T: Quantitation and distribution analysis of glial fibrillary acidic protein in human glioma cells in culture. J Neuropathol Exp Neurol 48:560-567, 1989
25. Iwadate Y, Fujimoto S, Tagawa M, et al: Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 69:226-240, 1996
26. Iwasaki K, Rogers LR, Barnett GH, et al: Effects of recombinant tumor necrosis factor-a on three-dimensional growth, morphology, and invasiveness of human glioblastoma cells in vitro. J Neurosurg 78:952-958, 1993
27. Kastan MB, Onyekwere O, Sidransky D, et al: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991
28. Kizaki M, Ueno H, Yamazoe Y, et al: Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome p450 and p-glycoprotein. Blood 87:725-733, 1996
29. Kondo S, Yin D, Morimura T, et al: Combination therapy with cisplatin and nifedipine inducing apoptosis in multidrug-resistant human glioblastoma cells. J Neurosurg 82:469-474, 1995
30. Korosue K, Takeshita I, Mannoji H, et al: Interferon effects on multiplication, cytoplasmic protein and GFAP content, and morphology in human glioma cells. J Neurooncol 1:69-76, 1983
31. Lehtinen SK, Rahkila P, Helenius M, et al: Down-regulation of transcription factors AP-1, Sp-1, and NF-κB precedes myucyte differentiation. Biochem Biophys Res Commun 229:36-43, 1996
32. Louis DN: The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53:11-21, 1994
33. Lowe SW, Ruley HE, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cells 74: 957-967, 1993
34. Magni M, Meldolesi J, Pandiella A: Ionic events induced by epidermal growth factor. Evidence that hyperpolarization and stimulated cation influx play a role in the stimulation of cell growth. J Biol Chem 266:6329-6335, 1991
35. Maria BL, Steck PA, Yung WKA, et al: The modulation of astrocytic differentiation in cells derived from a medulloblastoma surgical specimen. J Neurooncol 7:329-338, 1989
36. Marushige Y, Marushige K, Koestner A: Chemical control of growth and morphological characteristics of anaplastic glioma cells. Anticancer Res 9:1729-1736, 1989
37. Matsumoto H, Shimura M, Omatsu T, et al: p53 proteins accumulated by heat stress associate with heat shock proteins HSP72/HSC73 in human glioblastoma cell lines. Cancer Lett 87:39-46, 1994
38. McCachren SS Jr, Nichols J, Kaufman RE, et al: Dibutyryl cyclic adenosine monophosphate reduces expression of c-myc during HL-60 differentiation. Blood 68:412-416, 1986
39. Merzak A, Raynal S, Rogers JP, et al: Human wild type p53 inhibits cell proliferation and elicits dramatic morphological changes in human glioma cell lines in vitro. J Neurol Sci 127: 125-133, 1994
40. 2+ influx in human neutrophils is secondary to the emptying of intracellular calcium stores. Biochem J 277:73-79, 1991
41. Ogawa N, Fujiwara T, Kagawa S, et al: Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agents. Int J Cancer 73:367-370, 1997
42. Peppelenbosch MP, Tertoolen LG Jr, de Laat SW: Epidermal growth factor-activated calcium and potassium channels. J Biol Chem 266:19938-19944, 1991
43. Rozengurt E: Early signals in mitogenic response. Science 234:161-164, 1986
44. Rutka JT, Giblin JR, Apodaca G, et al: Inhibition of growth and induction of differentiation in a malignant human glioma cell line by normal leptomeningeal extracellular matrix proteins. Cancer Res 47:3515-3522, 1987
45. Rutka JT, Hubbard SL, Fukuyama K, et al: Effects of antisense glial fibrillary acidic protein complementary DNA on the growth, invasion, and adhesion of human astrocytoma cells. Cancer Res 54:3267-3272, 1994
46. Schiffer D, Giordana MT, Germano I, et al: Anaplasia and heterogeneity of GFAP expression in gliomas. Tumori 72: 163-170, 1986
47. Takahashi H, Abe M, Sugawara T, et al: Clotrimazole, an imidazole antimycotic, is a potent inhibitor of angiogenesis. Jpn J Cancer Res 89:445-451, 1998
48. Tsien RW, Tsien RY: Calcium channels, stores, and oscillations. Annu Rev Cell Biol 6:715-760, 1990
49. U HS, Espiritu OD, Kelley PY, et al: The role of epidermal growth factor receptor in human gliomas: II. The control of glial process extension and the expression of glial fibrillary acidic protein. J Neurosurg 82:847-857, 1995
50. 3 and chromaffin cells by imidazole antimycotics and other cytochrome P450 blockers. FASEB J 6:2742-2747, 1992